Akamai Technologies (AKAM) vs HealthEquity (HQY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Akamai Technologies (AKAM) has outperformed HealthEquity (HQY) over the past year, gaining 41.7% versus a loss of 0.2%. Over five years, HQY leads with a +47.3% price change compared with +0.6% for AKAM. Akamai Technologies is the larger company by market cap ($15.37 billion vs $7.66 billion), about 2.0 times the size, while HealthEquity is growing revenue faster (+9.5% vs +5.4%).
On valuation, Akamai Technologies trades at a lower forward P/E (15.6x vs 16.8x for HealthEquity). HealthEquity converts more of its revenue into profit, with a net margin of 16.4% versus 10.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKAM | HQY |
|---|---|---|
| Share price | $106.95 | $92.61 |
| Market cap | $15.37B | $7.66B |
| 1-day change | +6.00% | -0.47% |
| YTD return | +22.58% | +1.09% |
| 1-year return | +41.66% | -0.18% |
| 5-year return | +0.59% | +47.35% |
| P/E ratio (TTM) | 36.50 | 33.43 |
| Forward P/E | 15.62 | 16.84 |
| EPS (TTM) | $2.93 | $2.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.21B | $1.31B |
| Revenue growth (YoY) | +5.44% | +9.47% |
| Net income (latest FY) | $452.03M | $215.20M |
| Gross margin | 58.95% | 69.52% |
| Operating margin | 13.47% | 24.55% |
| Net margin | 10.74% | 16.38% |
| 52-week high | $165.45 | $107.62 |
| 52-week low | $70.82 | $72.76 |
| Distance from 52-week high | -35.36% | -13.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +48.55% | +28.85% |
| Average volume | 4.15M | 844.82K |
| Shares outstanding | 143.72M | 82.72M |
| Employees | 11,000 | 2,814 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Business Services | Business Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Akamai Technologies is about 2.0 times larger than HealthEquity by market value ($15.37B vs $7.66B).
- AKAM has outperformed HQY by 41.8 percentage points over the past year.
- HealthEquity is more profitable, keeping 16.4 cents of every revenue dollar as net income versus 10.7 cents for Akamai Technologies.
About Akamai Technologies
AKAM stock →Akamai Technologies, Inc. engages in the provision of security, delivery, and cloud computing solutions in the United States and internationally.
Consumer Discretionary · Business Services · 11,000 employees
About HealthEquity
HQY stock →HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States.
Consumer Discretionary · Business Services · 2,814 employees
AKAM vs HQY FAQ
Which is bigger, Akamai Technologies or HealthEquity?
Akamai Technologies (AKAM) is larger, with a market capitalization of $15.37B compared with $7.66B for HealthEquity (HQY).
Which stock has performed better over the past year, AKAM or HQY?
AKAM returned +41.66% over the past 12 months, compared with -0.18% for HQY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AKAM or HQY?
HQY has the lower trailing P/E at 33.4, versus 36.5 for AKAM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Akamai Technologies and HealthEquity in the same industry?
Yes. Both are classified in the Business Services industry within the Consumer Discretionary sector.